Shoreline Biosciences secures $140M for off-the-shelf NK cell therapies for cancer

Healthcare

Acute myelocytic leukemia, AML

Gilead Sciences and BeiGene, which started research alliances with Shoreline Biosciences earlier this year, are among the investors in the biotech’s latest financing. The preclinical-stage company technology develops cell therapies for cancer by using natural killer cells.

Leave a Reply